Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, multinational, randomised, double blind, single dummy, parallel group, placebo-controlled trial to investigate the dose-response and safety of Fentanyl TAIFUN 100 µg, 200 µg, 400 µg in the treatment of breakthrough pain in patients with cancer on maintenance opioid therapy for persistent pain.

Next Previous
X
Search
Trial Profile

A multicentre, multinational, randomised, double blind, single dummy, parallel group, placebo-controlled trial to investigate the dose-response and safety of Fentanyl TAIFUN 100 µg, 200 µg, 400 µg in the treatment of breakthrough pain in patients with cancer on maintenance opioid therapy for persistent pain.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary) ; Fentanyl
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Acronyms FIND
  • Sponsors LAB Pharma

    • Most Recent Events

    • 22 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top